Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer’s Antithrombotic Fragmin Recommended For Use In Cancer Patients

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA's Oncologic Drugs Advisory Committee unanimously recommended approval of an sNDA for Pfizer's low molecular weight heparin Fragmin for treatment and prevention of venous thromboembolism in cancer patients

You may also be interested in...



Fragmin Clears FDA For VTE In Cancer Patients

FDA clears Pfizer/Eisai’s low molecular weight heparin following oncology panel’s unanimous recommendation for approval.

Fragmin Clears FDA For VTE In Cancer Patients

FDA clears Pfizer/Eisai’s low molecular weight heparin following oncology panel’s unanimous recommendation for approval.

Eisai Eyes Oncology Franchise With Acquisition Of Ligand Products

Company may also hire Ligand personnel in addition to purchase of Ontak, Targretin and Panretin.

Related Content

Topics

UsernamePublicRestriction

Register

OM007016

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel